vs

Side-by-side financial comparison of Community West Bancshares (CWBC) and RIGEL PHARMACEUTICALS INC (RIGL). Click either name above to swap in a different company.

RIGEL PHARMACEUTICALS INC is the larger business by last-quarter revenue ($69.8M vs $38.3M, roughly 1.8× Community West Bancshares). On growth, RIGEL PHARMACEUTICALS INC posted the faster year-over-year revenue change (21.2% vs 11.6%). Over the past eight quarters, RIGEL PHARMACEUTICALS INC's revenue compounded faster (53.7% CAGR vs 36.0%).

Community West Bancshares is a registered bank holding company headquartered in California. It wholly owns Community West Bank under the Bank Holding Company Act.

Rigel Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing targeted small molecule therapies for autoimmune, inflammatory, and hematologic diseases. Its approved flagship product treats adult immune thrombocytopenia, with primary operations and core markets in the United States, addressing unmet medical needs for underserved patient groups.

CWBC vs RIGL — Head-to-Head

Bigger by revenue
RIGL
RIGL
1.8× larger
RIGL
$69.8M
$38.3M
CWBC
Growing faster (revenue YoY)
RIGL
RIGL
+9.6% gap
RIGL
21.2%
11.6%
CWBC
Faster 2-yr revenue CAGR
RIGL
RIGL
Annualised
RIGL
53.7%
36.0%
CWBC

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CWBC
CWBC
RIGL
RIGL
Revenue
$38.3M
$69.8M
Net Profit
$268.1M
Gross Margin
91.5%
Operating Margin
40.0%
33.2%
Net Margin
384.0%
Revenue YoY
11.6%
21.2%
Net Profit YoY
1769.2%
EPS (diluted)
$0.58
$14.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CWBC
CWBC
RIGL
RIGL
Q4 25
$38.3M
$69.8M
Q3 25
$37.9M
$69.5M
Q2 25
$35.7M
$101.7M
Q1 25
$34.8M
$53.3M
Q4 24
$34.3M
$57.6M
Q3 24
$31.3M
$55.3M
Q2 24
$30.5M
$36.8M
Q1 24
$20.7M
$29.5M
Net Profit
CWBC
CWBC
RIGL
RIGL
Q4 25
$268.1M
Q3 25
$10.9M
$27.9M
Q2 25
$7.8M
$59.6M
Q1 25
$8.3M
$11.4M
Q4 24
$14.3M
Q3 24
$3.4M
$12.4M
Q2 24
$-6.3M
$-1.0M
Q1 24
$3.7M
$-8.2M
Gross Margin
CWBC
CWBC
RIGL
RIGL
Q4 25
91.5%
Q3 25
93.2%
Q2 25
95.6%
Q1 25
91.7%
Q4 24
89.9%
Q3 24
85.5%
Q2 24
92.4%
Q1 24
93.1%
Operating Margin
CWBC
CWBC
RIGL
RIGL
Q4 25
40.0%
33.2%
Q3 25
39.8%
40.9%
Q2 25
30.2%
60.1%
Q1 25
32.7%
23.9%
Q4 24
31.0%
28.9%
Q3 24
13.3%
25.4%
Q2 24
-25.9%
1.2%
Q1 24
23.2%
-23.6%
Net Margin
CWBC
CWBC
RIGL
RIGL
Q4 25
384.0%
Q3 25
28.7%
40.2%
Q2 25
22.0%
58.6%
Q1 25
23.8%
21.5%
Q4 24
24.9%
Q3 24
10.8%
22.5%
Q2 24
-20.7%
-2.8%
Q1 24
17.8%
-27.9%
EPS (diluted)
CWBC
CWBC
RIGL
RIGL
Q4 25
$0.58
$14.11
Q3 25
$0.57
$1.46
Q2 25
$0.41
$3.28
Q1 25
$0.44
$0.63
Q4 24
$0.29
$0.82
Q3 24
$0.18
$0.70
Q2 24
$-0.33
$-0.06
Q1 24
$0.31
$-0.47

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CWBC
CWBC
RIGL
RIGL
Cash + ST InvestmentsLiquidity on hand
$119.0M
$155.0M
Total DebtLower is stronger
$69.5M
$52.5M
Stockholders' EquityBook value
$409.6M
$391.5M
Total Assets
$3.7B
$513.6M
Debt / EquityLower = less leverage
0.17×
0.13×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CWBC
CWBC
RIGL
RIGL
Q4 25
$119.0M
$155.0M
Q3 25
$121.6M
$137.1M
Q2 25
$134.4M
$108.4M
Q1 25
$148.4M
$77.1M
Q4 24
$120.4M
$77.3M
Q3 24
$149.0M
$61.1M
Q2 24
$109.7M
$49.1M
Q1 24
$61.0M
$49.5M
Total Debt
CWBC
CWBC
RIGL
RIGL
Q4 25
$69.5M
$52.5M
Q3 25
$60.0M
Q2 25
$60.0M
Q1 25
$60.0M
Q4 24
$69.9M
$60.0M
Q3 24
$60.0M
Q2 24
$60.0M
Q1 24
$60.0M
Stockholders' Equity
CWBC
CWBC
RIGL
RIGL
Q4 25
$409.6M
$391.5M
Q3 25
$397.6M
$117.6M
Q2 25
$380.0M
$81.9M
Q1 25
$372.2M
$18.6M
Q4 24
$362.7M
$3.3M
Q3 24
$363.5M
$-14.6M
Q2 24
$350.2M
$-29.9M
Q1 24
$211.7M
$-31.7M
Total Assets
CWBC
CWBC
RIGL
RIGL
Q4 25
$3.7B
$513.6M
Q3 25
$3.6B
$242.5M
Q2 25
$3.6B
$206.7M
Q1 25
$3.6B
$176.0M
Q4 24
$3.5B
$164.0M
Q3 24
$3.5B
$139.4M
Q2 24
$3.5B
$128.4M
Q1 24
$2.4B
$126.5M
Debt / Equity
CWBC
CWBC
RIGL
RIGL
Q4 25
0.17×
0.13×
Q3 25
0.51×
Q2 25
0.73×
Q1 25
3.23×
Q4 24
0.19×
18.25×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CWBC
CWBC
RIGL
RIGL
Operating Cash FlowLast quarter
$46.1M
$22.0M
Free Cash FlowOCF − Capex
$43.6M
FCF MarginFCF / Revenue
113.9%
Capex IntensityCapex / Revenue
6.6%
Cash ConversionOCF / Net Profit
0.08×
TTM Free Cash FlowTrailing 4 quarters
$77.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CWBC
CWBC
RIGL
RIGL
Q4 25
$46.1M
$22.0M
Q3 25
$13.2M
$24.0M
Q2 25
$11.5M
$30.5M
Q1 25
$11.1M
$-893.0K
Q4 24
$22.2M
$14.5M
Q3 24
$7.8M
$21.7M
Q2 24
$5.2M
$302.0K
Q1 24
$4.0M
$-5.0M
Free Cash Flow
CWBC
CWBC
RIGL
RIGL
Q4 25
$43.6M
Q3 25
$12.8M
Q2 25
$10.6M
Q1 25
$10.8M
Q4 24
$17.2M
Q3 24
$5.2M
Q2 24
$4.8M
Q1 24
$3.6M
FCF Margin
CWBC
CWBC
RIGL
RIGL
Q4 25
113.9%
Q3 25
33.7%
Q2 25
29.6%
Q1 25
30.9%
Q4 24
50.0%
Q3 24
16.7%
Q2 24
15.7%
Q1 24
17.3%
Capex Intensity
CWBC
CWBC
RIGL
RIGL
Q4 25
6.6%
Q3 25
1.1%
Q2 25
2.7%
Q1 25
0.9%
Q4 24
14.7%
Q3 24
8.1%
Q2 24
1.4%
Q1 24
2.1%
Cash Conversion
CWBC
CWBC
RIGL
RIGL
Q4 25
0.08×
Q3 25
1.21×
0.86×
Q2 25
1.47×
0.51×
Q1 25
1.33×
-0.08×
Q4 24
1.01×
Q3 24
2.29×
1.75×
Q2 24
Q1 24
1.09×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons